

1 Extralabel drug use in cattle with case examples
2 Virginia R. Fajt, DVM, PhD, DACVCP
3 College of Veterinary Medicine & Biomedical Sciences, Texas A&M University

4
5 Abstract

6 Cattle veterinarians have the responsibility of selecting, using, dispensing, and prescribing drugs
7 in a legal manner. The process for drug approval for food animals in the U.S. is briefly reviewed,
8 and the federal law allowing extralabel drug use is detailed. Application of regulations to
9 exemplar case scenarios are presented for illustration and discussion.

10

11 *Disclaimer*

12 I am not a lawyer and have not been employed by regulatory agencies; therefore, the following
13 information is my interpretation only. Legal representation should be sought, or the relevant laws
14 and regulations should be reviewed, if additional clarification is required.

15

16 Background for making legal drug selection and use decisions

17 Veterinarians have the privilege of drug prescribing as part of the practice of veterinary medicine
18 and therefore the responsibility and obligation to use, dispense, or prescribe drugs in a legal
19 manner. Navigating local, state, and federal laws that touch on those responsibilities can be
20 challenging, and the goal of this presentation is to share important rules and laws in the United
21 States and the application of those rules and laws to case scenarios.

22

23 *Definition of a drug*

24 To set the stage for discussions about drug use, federal law defines what and how drugs can be
25 sold via interstate commerce in the Federal Food Drug and Cosmetic Act (FFDCA), the Virus
26 Toxins and Serums Act, and the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). A
27 drug is defined in 21 U.S. Code 321 (in the FFDCA) as follow:

28 “(g)(1) The term "drug" means (A) articles recognized in the official United States
29 Pharmacopoeia,¹ official Homoeopathic Pharmacopoeia of the United States, or official
30 National Formulary, or any supplement to any of them; and (B) articles intended for use
31 in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other
32 animals; and (C) articles (other than food) intended to affect the structure or any function
33 of the body of man or other animals; and (D) articles intended for use as a component of
34 any article specified in clause (A), (B), or (C).”

35

36 *Relevant federal agencies*

37 Most veterinary drugs are under the jurisdiction of the Food and Drug Administration(FDA)
38 Center for Veterinary Medicine (CVM), and in addition, if they fall into the categories of
39 controlled substances, can be regulated by the Drug Enforcement Administration (DEA). Human
40 drugs are also under the jurisdiction of FDA but a different center, the Center for Drug
41 Evaluation and Research (CDER).The exceptions to drugs being approved by the FDA CVM are
42 (1) drugs that fall under the U.S. Department of Agriculture (USDA) due to their nature as
43 biological products (9 CFR 101) “...which are intended for use in the treatment of animals and
44 which act primarily through the direct stimulation, supplementation, enhancement, or modulation
45 of the immune system or immune response,” and (2) drugs that fall under the Environmental

46 Protection Agency (EPA) because they are pesticides and therefore regulated by FIFRA (7 U.S.
47 Code 136).

48

49 There is no federal regulation of dietary supplements or nutraceuticals intended for animals.

50 These products have no oversight as to product safety or efficacy. As long as the manufacturer of
51 a supplement does not make a drug claim, there is very little regulators can do to control the sale
52 of the supplement. However, if a manufacturer makes a claim on a website, in promotional
53 materials, or on the label, they are at risk of a warning from the FDA CVM and could be ordered
54 to stop production and sale of such a product, since it is an unapproved drug (see previous
55 definition of a drug: if you intend to use the product as a drug, it is a drug, and drugs that are not
56 approved are in violation of federal law).

57

58 Human supplements different from supplements intended for animals; they fall under the Dietary
59 Supplement and Health Education Act, which only prevents manufacturers from marketing
60 products that are adulterated or misbranded, for example, if they make drug claims. Dietary
61 supplements intended for humans are not required to demonstrate efficacy.

62

63 *Drug approval*

64 Drugs are approved by the FDA CVM in a standardized manner in order to demonstrate safety
65 and efficacy for the intended use. Phases of drug approval include a preclinical phase, in which
66 novel compounds are evaluated for therapeutic effects and for toxicity in vitro and in laboratory
67 animals; Phase 1, in which a small number of healthy animals are administered the drug to
68 evaluate safety and drug disposition; Phase 2, in which a small number of animals with the target

69 condition are administered the drug to evaluate safety and efficacy; and Phase 3, in which a large
70 number of animals with the target condition and in their natural environment, e.g., in production
71 settings or private veterinary practices, are administered the drug in its final formulation to
72 evaluate safety (target animal and human) and efficacy. In addition to studies that demonstrate
73 safety and efficacy, drug sponsors must also submit the manufacturing plan and all of the
74 labeling materials, including the insert, packaging, and Freedom of Information Summary.
75 Sponsors also must evaluate environmental impact of the drug.

76

77 Categories of veterinary drug approvals include approved, conditionally approved, and indexed.
78 Approved drugs can be marketed, and they can also be used in an extralabel manner, under
79 certain circumstances (see below). Conditionally approved drugs can be marketed while the
80 sponsor is still demonstrating efficacy; these are generally drugs for minor uses or minor species,
81 can only be sold for up to 5 years with annual renewal before they must be either fully approved
82 or no longer marketed. They cannot be used in an extralabel manner. These drugs have the
83 designation “CA” and then a number, e.g., Fidoquel-CA1, a phenobarbital-containing product
84 conditionally approved for seizure control in dogs. Indexed drugs have not demonstrated safety
85 or efficacy and is only for drugs in which performing studies is unlikely; food animal drugs are
86 not eligible for indexing.

87

88 Marketing categories of drugs are over-the-counter (OTC), prescription (designated on human-
89 labeled drugs as Rx), and veterinary feed directive (VFD). OTC drugs do not require a
90 veterinarian’s oversight, prescription drugs can only be sold under the direction of a veterinarian,
91 and VFD drugs require a veterinarian’s order to be sold or to be fed. It is important to note,

92 however, that the OTC designation is only valid if the drug is being used as labeled. For
93 example, human OTC drugs prescribed for animals require a prescription or a veterinarian's label
94 (as described in extralabel drug use regulations; see below and other resources).

95
96 To summarize, veterinarians can be confident that drugs approved by the FDA CVM are
97 effective for the indication on the label, that the target animal and human safety have been
98 characterized, and that they are manufactured using standardized practices in inspected facilities.
99 Drugs that have not gone through the approval process do not have this assurance; for example,
100 compounded drugs have no standardized manufacturing and have not been assessed for safety or
101 efficacy. This is why the first choice for drug selection is a drug approved for the condition of
102 interest if one exists. This is the first step in the algorithm for extralabel use justification: there is
103 no need for extralabel drug use if a labeled drug is available.

104

105 *State laws related to drug selection and use*

106 State laws define veterinary practice in their state practice acts. The American Associations of
107 Veterinary State Boards provides contact information for all state veterinary boards at
108 <https://www.aavsb.org/public-resources/find-regulatory-board-information>. State law also
109 governs how drugs can be sold and distributed via state pharmacy acts, which may differ across
110 states.

111

112 *Federal laws related to drug selection and use*

113 Federal law allows veterinarians to use and prescribe drugs in animals in an extralabel manner
114 under specific circumstances. This law was first passed in 1994 as the Animal Medicinal Drug

115 Use Clarification Act (AMDUCA) and has been amended periodically since then. Extralabel is
116 defined as anything not included on the label, so use in a different species of animal, by a
117 different route of administration, at a different dose, at a different frequency, at a different
118 duration, for a different indication, or anything else not on the label. Under AMDUCA,
119 extralabel use is not permitted for non-therapeutic purposes (such as growth promotion or
120 reproduction), by or on the order of a layperson, if it results in an unsafe or violative residue, or
121 of feed additives. Extralabel use of specified drugs or drug groups are not permitted – these are
122 laid out in 21 CFR 530.41 ([https://www.ecfr.gov/current/title-21/chapter-I/subchapter-E/part-
123 530/subpart-E/section-530.41](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-E/part-530/subpart-E/section-530.41)).

124

125 The following hierarchy (also laid out in the AVMA algorithm at
126 https://zingtree.com/deploy/tree.php?z=embed&tree_id=673679905) can help veterinarians
127 identify when extralabel use might be permissible:

- 128 - If there is an FDA-approved product labeled for the animal species, indication, needed
129 dosage form and concentration, that is clinically effective, use the labeled product.
- 130 - If there is no FDA-approved product as described above, extralabel use of a drug
131 approved in food animals is the next best option, as long as it is not on the prohibited list,
132 it is not for use in or on animal feed, and there is adequate information to establish an
133 extended withdrawal time.
- 134 - If there is no FDA-approved product approved in a food animal species, a product
135 approved for non-food animals or for humans may be used.

136

137 Regardless of the justification of extralabel use, an extended withdrawal time must be
138 established, label and record requirements must be met, and animals must be identified. The
139 Food Animal Residue Avoidance Databank is a resource for withdrawal time estimates, but the
140 veterinarian is ultimately responsible for any residues that arise from extralabel use.

141

142 *General categories of legality of drug use and selection*

143 Legal

- 144 - Drugs used exactly as on the label (same species, same indication, same regimen –
145 dose/route/frequency/duration)
- 146 - Extralabel use for therapeutic purposes, by or on the order of a licensed veterinarian with
147 a VCPR, that does not cause a residue above a tolerance or is a threat to public health,
148 and that include specific labeling, record-keeping, and disclosure to the client (in some
149 jurisdictions)

150 Illegal but of low regulatory priority

- 151 - Use of a drug compounded from bulk in a non-food animal (see GFI 256)
- 152 - Use of a feed additive extralabel in a minor species (see CPG 615.115)
 - 153 ○ This guide states that veterinarians will not be prosecuted for using feed additive
154 drugs extralabel as long as the provisions are followed. This document does not
155 make these uses legal; it just identifies an area of low regulatory priority.

156 Unclear legality

- 157 - Extralabel use of a USDA-approved drug

158 Illegal

- 159 - Extralabel uses listed in 21 CFR 530.41 (e.g., drugs such as chloramphenicol and
- 160 enrofloxacin in food animals)
- 161 - Extralabel use in or on animal feed (whether OTC or VFD)
- 162 - Extralabel use for production or non-therapeutic uses
- 163 - Use of a drug that is not approved, e.g., drug approved in another country, CBD used as a
- 164 drug
- 165 - Extralabel use of an EPA-approved drug
- 166 - Use of a drug compounded from bulk in a food animal
- 167 - Some uses of controlled substances, e.g., with improper documentation or prescriptions
- 168 - Use of conditionally approved drugs extralabel
- 169 - Extralabel use directed by a layperson
- 170 - Extralabel use without a VCPR

171

172 Case scenarios to illustrate legal issues

173

174 The scenarios below or similar ones will be reviewed during the presentation and provide
175 opportunities for pointing out various aspects of legal and illegal extralabel drug use. The
176 interpretations of legality are the author's and could be modified by applicable laws and clinical
177 settings.

178

- 179 - Trenbolone-containing implant for estrus suppression in heifers
- 180 o Extralabel for a production use is illegal.
- 181 - Clenbuterol for growth promotion in steers

- 182 ○ Extralabel use of clenbuterol in food animals is illegal
- 183 - Enrofloxacin for colibacillois in pigs
- 184 ○ If used as labeled, would be legal.
- 185 - Enrofloxacin for colibacillosis in calves
- 186 ○ Extralabel use of fluoroquinolones is illegal.
- 187 - Clenbuterol for asthma in cats
- 188 ○ Extralabel use of clenbuterol is not illegal in non-food animals so this could be
- 189 legal.
- 190 - Metronidazole capsules for coccidiosis in goats
- 191 ○ Extralabel use of metronidazole in food animals is illegal.
- 192 - Horse-labeled ponazuril for coccidiosis in calves
- 193 ○ Extralabel use when there is a labeled product that is effective is illegal.
- 194 - Compounded ponazuril for coccidiosis in lambs
- 195 ○ Compounding from bulk drug is illegal.
- 196 - Chlortetracycline feed additive at 500 mg/head/day to control abortions in sheep
- 197 ○ Extralabel use of feed additives is illegal, but this would be of low regulatory
- 198 priority according to CPG 615.115.
- 199 - Acepromazine for the 4H steer
- 200 ○ Extralabel use for non-production purposes is illegal. In addition, not a legal
- 201 issue, but show rules may be zero tolerance so use during the show may be
- 202 disallowed.
- 203 - Itraconazole purchased in Mexico for dermatophytosis in cats
- 204 ○ Drugs approved in other countries are illegal under the FDCA.

205

206 Resources for additional information

207

208 AVMA Definitions of antimicrobial use for treatment, control, and prevention,

209 <https://www.avma.org/resources-tools/avma-policies/avma-definitions-antimicrobial-use->

210 [treatment-control-and-prevention](https://www.avma.org/resources-tools/avma-policies/avma-definitions-antimicrobial-use-treatment-control-and-prevention)

211

212 DailyMed database of drug labels, National Library of Medicine/National Institutes of Health,

213 <https://dailymed.nlm.nih.gov/dailymed/>

214

215 Definition of biological products, 9 CFR 101, <https://www.ecfr.gov/current/title-9/chapter->

216 [1/subchapter-E/part-101](https://www.ecfr.gov/current/title-9/chapter-1/subchapter-E/part-101)

217

218 FARAD (Food Animal Residue Avoidance Databank), <http://www.farad.org/>

219

220 FDA Center for Veterinary Medicine

221 - Database of Approved Drugs, Animal Drugs @ FDA,

222 <https://animaldrugsatfda.fda.gov>

223 - Antimicrobial resistance resources, <https://www.fda.gov/animal-veterinary/safety->

224 [health/antimicrobial-resistance](https://www.fda.gov/animal-veterinary/safety-health/antimicrobial-resistance)

225 - Transition of over-the-counter medically important antimicrobials for animals to

226 prescription status, <https://www.fda.gov/animal-veterinary/cvm-updates/fda->

227 [announces-transition-over-counter-medically-important-antimicrobials-animals-](#)
228 [prescription-status](#)
229 - CPG Sec 615.115 Extralabel Use of Medicated Feeds for Minor Species,
230 [https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cpg-sec-615115-extralabel-use-medicated-feeds-minor-species)
231 [615115-extralabel-use-medicated-feeds-minor-species](#)
232
233 “From an Idea to the Marketplace: The Journey of an Animal Drug through the Approval
234 Process,” [https://www.fda.gov/animal-veterinary/animal-health-literacy/idea-marketplace-](https://www.fda.gov/animal-veterinary/animal-health-literacy/idea-marketplace-journey-animal-drug-through-approval-process)
235 [journey-animal-drug-through-approval-process](#)
236
237 Tolerances for residues of new animal drugs in food, 21 CFR 556,
238 <https://www.ecfr.gov/current/title-21/chapter-I/subchapter-E/part-556>
239